New Alvotech partnerships in South Africa and China

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

New Alvotech partnerships in South Africa and China

INICIO/Noticias Farmacéuticas | Posted 11/12/2020 0 Post your comment

Iceland-based biopharmaceutical company Alvotech entered into two partnerships in November 2020, that will expand their reach into South Africa and China.

Alvotech in South Africa
Alvotech has entered into an exclusive partnership with Cipla Medpro to bring key biosimilars to patients in emerging markets such as South Africa. Under the Alvotech-Cipla partnership, Alvotech will be responsible for development and supply of the products, while responsibility for registration and commercialization falls to Cipla which has a leading presence in the South African market. Together, their biosimilar portfolio will include five biosimilar medicines – two oncology treatments and three auto-immune disease treatments.

Alvotech in China
In addition, Alvotech and the China joint venture company of Alvotech ehf and Changchun High & New Technology Industries (Group) Inc – known as Alvotech and CCHT Biopharmaceutical – have partnered with Chinese company, the Yangtze River Pharmaceutical Group. This aims to form an exclusive strategic partnership for the commercialization of eight copy biologicals in China.

China is the world’s second largest pharmaceutical market and Yangtze River Pharmaceutical Group is the country’s largest pharmaceutical company. Thus, through the partnership, Alvotech and Alvotech & CCHT Biopharmaceutical gain valuable access to Yangtze River Pharmaceutical’s strong brand reputation and market experience in China. Under the agreement, Alvotech and Alvotech & CCHT Biopharmaceutical Co will be responsible for the development, registration and supply of their copy biologicals in China. Yangtze River Pharmaceutical will take responsibility for their commercialization.

Initially, the pipeline contains copy biological candidates for treatment of conditions in the fields of autoimmunity, ophthalmology and oncology, and for severe immune and inflammatory conditions. They will be manufactured in a new state-of-the-art biopharmaceutical facility, being built in Changchun, China, the first phase of which is expected to be completed in 2021.

These new partnerships follow Alvotech’s other recent global partnerships including with Teva Pharmaceuticals in the US [1], JAMP Pharma in Canada [2] and Stada in Europe [3].

Related articles
Alvotech and Cipla Gulf partnership announced

Alvotech signs agreement for ustekinumab biosimilar Stelara in Japan

Alvotech makes deal with Fuji Pharma for biosimilars in Japan

LATIN AMERICAN FORUM We are pleased to announce, that starting January 2021, the launch of a new section on GaBI Online, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America. Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

References
1. GaBI Online - Generics and Biosimilars Initiative. Teva changes course in Japan and the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Dec 11]. Available from: www.gabionline.net/Pharma-News/Teva-changes-course-in-Japan-and-the-US
2. GaBI Online - Generics and Biosimilars Initiative. New biosimilars partnerships from Alvotech and Biocon [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Dec 11]. Available from: www.gabionline.net/Pharma-News/New-biosimilars-partnerships-from-Alvotech-and-Biocon
3. GaBI Online - Generics and Biosimilars Initiative. Alvotech signs agreements with Stada and Yas Holding [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Dec 11].
Available from: www.gabionline.net/Pharma-News/Alvotech-signs-agreements-with-Stada-and-Yas-Holding

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.